SCHEMBL4252227

SCHEMBL4252227

CN(C(=O)c1ccc(Cl)c(Cl)c1)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.58
PLAU P00749 1/20 0.56
ALDH1A1 P00352 3/20 0.56
PTGDR2 Q9Y5Y4 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.54
MCHR1 Q99705 1/20 0.54
KDM4E B2RXH2 1/20 0.54
KMT2A Q03164 1/20 0.54
HTT P42858 2/20 0.54
EGFR P00533 1/20 0.54
ERBB2 P04626 1/20 0.54
P2RX7 Q99572 1/20 0.52
TSHR P16473 1/20 0.52
ATM Q13315 1/20 0.51
LMNA P02545 2/20 0.51
GPBAR1 Q8TDU6 1/20 0.51
NPC1 O15118 2/20 0.50
HPGD P15428 2/20 0.50
RAB9A P51151 2/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3110778 0.86 ALDH1A1 (0.64) POLBPLAUALDH1A1SMN1; SMN2KDM4E
SCHEMBL9001653 0.82 KMT2A (0.75) POLBPLAUALDH1A1KDM4EKMT2A
SCHEMBL3110750 0.81 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2KMT2AHTTATM
SCHEMBL2158629 0.81 HSD17B1 (0.47) POLBPLAUALDH1A1PTGDR2SMN1; SMN2
SCHEMBL12311615 0.81 KMT2A (0.64) POLBPLAUALDH1A1SMN1; SMN2KDM4E
SCHEMBL9001650 0.80 MAOA (0.63) POLBPLAUALDH1A1SMN1; SMN2KDM4E
SCHEMBL11675105 0.80 TSHR (0.52) ALDH1A1SMN1; SMN2KMT2ATSHRNPC1
SCHEMBL9001647 0.80 ATM (0.72) POLBPLAUKDM4EKMT2AHTT
SCHEMBL23558023 0.79 ATM (0.58) POLBPLAUALDH1A1SMN1; SMN2KDM4E
SCHEMBL9001684 0.78 PLAU (0.57) POLBPLAUKDM4EKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
WO-2009016088-A1 THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 WO disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS GABBR1, GABBR2, CHRM2 POLB 4586/4885PLAU 3750/4885ALDH1A1 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.